Valeant Continues to Grow by Acquisition

By Bizclik Editor

 

Valeant Pharmaceuticals and its subsidiaries announced today that it has signed an agreement to acquire Ortho Dermatologics division of Janssen Pharmaceuticals. Valued at $345 million, Valeant will pay Janssen for its assets.

Janssen’s Ortho Dermatologics division has a widely known portfolio including prescription brands RETIN-A MICRO ®, ERTACZO ®, and RENOVA ®. In 2010, the portfolio was valued at $150 million. The agreement is still subject to closing conditions and regulatory approvals.

"With the combination of this transaction and other recently announced transactions, Valeant is well on its way to being one of the leading companies in dermatology," stated J. Michael Pearson, chairman and chief executive officer. "We believe that dermatology remains an attractive therapeutic area for Valeant and we are pleased to able to add another strong franchise to our growing operations."

 

SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:

Click here to read the latest issue of Business Review Canada

 

Part of Ortho’s portfolio RETIN-A MICRO is a prescription-strength acne treatment mainly used by teens. Advertised as a treatment that clears skin in approximately two weeks and with around seven showing full results.

Clearly in a move to progress further dermatology solutions, this announcement from Valeant comes just after a similar announcement of an acquisition of Dermik, another dermatology specialization company.

Valeant Pharmaceuticals International is a Mississauga, Ontario based company that advertises itself as a “multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas neurology, dermatology, and branded generics.”

Share

Featured Articles

PwC's Kathryn Kaminsky – the role of boards on social issues

As Vice Chair Trust Solutions Co-Leader at PwC, Kathryn Kaminsky says boards play an important role in helping businesses take action on social issues

Why your business needs a Chief Transformation Officer

Responsible for driving growth and change, the Chief Transformation Officer is the latest addition to the C-suite as business undergoes major change

12 top AI and ML trends for the enterprise in 2023 – Dataiku

With 2023 likely to be a huge year for AI, experts from AI platform provider Dataiku deliver their enterprise AI and ML trends for the year ahead

From NYC to Hong Kong, the rise of the private members' club

Leadership & Strategy

Meet the CEO: Jill Stelfox of Panzura, exclusive interview

Leadership & Strategy

The best Michelin-starred restaurants that are meat-free

Sustainability